As of 2025-04-18, the EV/EBITDA ratio of Arrowhead Pharmaceuticals Inc (ARWR) is -3.13. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARWR's latest enterprise value is 1,901.10 mil USD. ARWR's TTM EBITDA according to its financial statements is -608.21 mil USD. Dividing these 2 quantities gives us the above ARWR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 13.4x | 12.2x |
| Forward P/E multiples | 14.0x - 15.1x | 14.5x |
| Fair Price | (64.43) - (61.78) | (61.73) |
| Upside | -673.3% - -649.6% | -649.2% |
| Date | EV/EBITDA |
| 2025-04-16 | -3.15 |
| 2025-04-15 | -3.49 |
| 2025-04-14 | -3.37 |
| 2025-04-11 | -3.25 |
| 2025-04-10 | -3.10 |
| 2025-04-09 | -3.25 |
| 2025-04-08 | -2.84 |
| 2025-04-07 | -2.90 |
| 2025-04-04 | -3.00 |
| 2025-04-03 | -3.31 |
| 2025-04-02 | -3.45 |
| 2025-04-01 | -3.34 |
| 2025-03-31 | -3.46 |
| 2025-03-28 | -3.71 |
| 2025-03-27 | -3.70 |
| 2025-03-26 | -3.73 |
| 2025-03-25 | -3.91 |
| 2025-03-24 | -4.09 |
| 2025-03-21 | -3.93 |
| 2025-03-20 | -4.00 |
| 2025-03-19 | -4.08 |
| 2025-03-18 | -4.00 |
| 2025-03-17 | -4.11 |
| 2025-03-14 | -4.06 |
| 2025-03-13 | -3.99 |
| 2025-03-12 | -4.15 |
| 2025-03-11 | -3.99 |
| 2025-03-10 | -4.02 |
| 2025-03-07 | -4.42 |
| 2025-03-06 | -4.58 |
| 2025-03-05 | -4.51 |
| 2025-03-04 | -4.45 |
| 2025-03-03 | -4.59 |
| 2025-02-28 | -4.86 |
| 2025-02-27 | -4.86 |
| 2025-02-26 | -4.93 |
| 2025-02-25 | -5.00 |
| 2025-02-24 | -4.85 |
| 2025-02-21 | -5.08 |
| 2025-02-20 | -5.32 |
| 2025-02-19 | -5.35 |
| 2025-02-18 | -5.20 |
| 2025-02-14 | -5.09 |
| 2025-02-13 | -4.90 |
| 2025-02-12 | -4.78 |
| 2025-02-11 | -4.85 |
| 2025-02-10 | -5.09 |
| 2025-02-07 | -5.16 |
| 2025-02-06 | -5.21 |
| 2025-02-05 | -5.16 |